Physician profile
Usha Sivakumar
NPI 1124001540
$6,685.03
in general payments reported to CMS, 2019-2025
46 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $278 · 2020: $559 · 2021: $1,001 · 2022: $962 · 2023: $1,372 · 2024: $1,241 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,885.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,353.24 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $908.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $834.47 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $459.56 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $390.38 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $374.76 | 2020-2025 | Prolia, Evenity, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.25 | 2020-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.72 | 2019-2025 | Jardiance |
| Pfizer INC. | $210.89 | 2019-2025 | |
| Abbott Laboratories | $152.97 | 2024-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $129.83 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $110.87 | 2020-2024 | Verquvo, Belsomra, Gardasil |
| Tactile Systems Technology INC | $100.78 | 2020-2024 | Flexitouch Plus, Entre Plus |
| Ironwood Pharmaceuticals, INC | $94.84 | 2020-2023 | Linzess |
| Exact Sciences Corporation | $77.64 | 2023-2025 | Cologuard Collection Kit |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Sivakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.